ArticlePharmacological reports : PR2026

The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer.

Cezary Miedziarek et al.PubMed ↗Publisher ↗

No numbers read from the abstract.